From Medscape Oncology

Genitourinary Cancers Symposium (GUCS) 2019

February 14 - 16, 2019; San Francisco, California

February 14 - 16, 2019 San Francisco, California

GUCS 2019 Darolutamide: New Standard of Care in Nonmetastatic CRPC? An investigational agent significantly extended metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
Medscape Medical News, February 15, 2019
GUCS 2019 Novel Radiotherapy Shows Promise in Heavily Pretreated mCRPC A novel targeted radiolabeled small molecule appears to improve overall survival in men with metastatic castration-resistant prostate cancer (mCRPC).
Medscape Medical News, February 14, 2019
GUCS 2019 Longer Survival in Black Men on Newer Prostate Cancer Drugs Black men with metastatic castration-resistant prostate cancer had longer overall survival than white patients when treated with newer hormone therapies.
Medscape Medical News, February 13, 2019

'Finally, Real Promise' for Prostate Cancers With No Therapy Two drugs have demonstrated clinically significant improvements in delaying the onset of metastatic disease by more than 20 months.
Medscape Medical News, Feb 05, 2018
'Cinderella' Cancer Gets Trial With Fairy-tale Ending Upper tract bladder cancer is a rare malignancy and as such is difficult to study in a phase 3 clinical trial. But a determined group of investigators pulled it off and appear to have changed practice.
Medscape Medical News, Feb 12, 2018
Practice-Changing Data at 2018 GUCS 'Cannot Be Ignored' A group of practice-changing trials presented at the 2018 Genitourinary Cancers Symposium highlights the growing importance of oncology subspecialty meetings, argues Dr David Graham.
Medscape Medical News, Feb 22, 2018

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Resource Center